Veterinary

Golub Capital Acted as Sole Lender on Unitranche Facility for Agilio Software

Retrieved on: 
Monday, February 19, 2024

Golub Capital acted as Sole Lender on a unitranche facility to support the acquisition of Agilio Software (“Agilio”) by Five Arrows and TA Associates (“TA”).

Key Points: 
  • Golub Capital acted as Sole Lender on a unitranche facility to support the acquisition of Agilio Software (“Agilio”) by Five Arrows and TA Associates (“TA”).
  • Terms of the deal were not disclosed.
  • “We are delighted to lead this transaction to support the acquisition of Agilio, which maintains an impressive growth trajectory.”
    The unitranche facility is composed of a revolver, term loan and a delayed draw term loan.
  • As of January 1, 2024, Golub Capital has completed over 70 platform and add-on transactions with software and technology companies in the last 12 months.

Butterfly Network, Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024

Retrieved on: 
Thursday, February 15, 2024

Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), a digital health company transforming care with handheld, whole-body ultrasound, today announced that it will report fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, after the market closes.

Key Points: 
  • Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), a digital health company transforming care with handheld, whole-body ultrasound, today announced that it will report fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, after the market closes.
  • Joseph DeVivo, President, Chief Executive Officer and Chairman of the Board, and Heather Getz, Executive Vice President and Chief Financial and Operations Officer, will host a conference call and webcast at 5:00 pm ET, February 28, 2024, to discuss the financial results and operational progress.
  • The conference call will be broadcast live in listen-only mode via a webcast on Butterfly’s Investor Relations website at Events & Presentations .
  • Also joining Butterfly will be key partners who will detail co-developed products.

Fernando Delgado joins Bond Vet as Chief Growth Officer

Retrieved on: 
Thursday, February 15, 2024

Bond Vet, a leading provider of veterinary primary and urgent care services in the United States, proudly announces the appointment of Fernando Delgado to the position of Chief Growth Officer (CGO).

Key Points: 
  • Bond Vet, a leading provider of veterinary primary and urgent care services in the United States, proudly announces the appointment of Fernando Delgado to the position of Chief Growth Officer (CGO).
  • Fernando joins Bond with over 20 years of marketing and business experience spanning multiple industries, including retail & hospitality, pharmaceuticals & life sciences, and consumer packaged goods.
  • “I’m thrilled to welcome Fernando to Bond Vet,” said Garrett Lewis, Chief Executive Officer.
  • In October 2023, they secured an additional $50 million from existing investors, including Warburg Pincus and Talisman Capital Partners, to continue their nationwide growth plans.

Internist Shirin Peters, M.D. of Bethany Medical Clinic, Shares Top Tips for the Challenges of Winter Allergies

Retrieved on: 
Thursday, February 15, 2024

has identified at-home recommendations to combat winter allergy symptoms, helping allergy sufferers manage triggers, ease concerns, and avoid future flare-ups.

Key Points: 
  • has identified at-home recommendations to combat winter allergy symptoms, helping allergy sufferers manage triggers, ease concerns, and avoid future flare-ups.
  • “Many associate seasonal allergies just with spring but winter presents a different challenge to allergy sufferers.
  • Moreover, simple lifestyle changes and at-home tips can help manage symptoms and bring some relief during these cooler months,” says Dr. Peters, with Bethany Medical Clinic.
  • Dr. Peters shares preventative measures to decrease your chances of winter and indoor allergies and lower your risk of developing sinusitis and nasal polyps.

Phibro Animal Health Corporation to Participate in Bank of America 2024 Animal Health Summit

Retrieved on: 
Wednesday, February 14, 2024

Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Bank of America 2024 Virtual Animal Health Summit.

Key Points: 
  • Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Bank of America 2024 Virtual Animal Health Summit.
  • Chief Financial Officer, Glenn David along with EVP Corporate Strategy, Dani Bendheim will address financial analysts and investors on Thursday, February 29, 2024, at 10:00 AM ET.
  • The live audio presentation will be available on the Phibro Animal Health Corporation Investor Relations Website at https://investors.pahc.com .
  • A replay of the session will be available and archived on the company’s website.

Rejuvenate Bio Announces Partnership with Leading Animal Health Company to Develop Gene Therapy for Canine Osteoarthritis

Retrieved on: 
Wednesday, February 14, 2024

Rejuvenate Bio today announced a partnership with a leading animal health company for the development and commercialization of its novel gene therapy technology for the treatment of canine osteoarthritis (OA), a complex chronic disease that affects dogs’ mobility and overall quality of life.

Key Points: 
  • Rejuvenate Bio today announced a partnership with a leading animal health company for the development and commercialization of its novel gene therapy technology for the treatment of canine osteoarthritis (OA), a complex chronic disease that affects dogs’ mobility and overall quality of life.
  • This agreement with the global company follows the agreement reached in 2022 with Phibro Animal Health and further validates the gene therapy technology developed by Rejuvenate Bio and their strategy to develop their breakthrough technology in both animal health and human health.
  • Canine osteoarthritis (OA) presents a significant challenge, being both painful and progressive, with a concerning prevalence rate.
  • “This partnership with a leading animal health company validates our technology and approach of utilizing gene therapy to treat chronic age-related diseases and ensures that this therapy will reach the dogs that need it.

Trupanion Reconvenes Council on Animal Health; Provides Data-Driven Update on ‘Mystery’ Canine Respiratory Illness

Retrieved on: 
Tuesday, February 13, 2024

Trupanion, Inc. (Nasdaq: TRUP), a leading provider of medical insurance for cats and dogs, reconvened world-renowned animal health and infectious disease authorities to continue the investigation into the reported uptick of on canine respiratory illness.

Key Points: 
  • Trupanion, Inc. (Nasdaq: TRUP), a leading provider of medical insurance for cats and dogs, reconvened world-renowned animal health and infectious disease authorities to continue the investigation into the reported uptick of on canine respiratory illness.
  • Dr. Steve Weinrauch, BVMS, MRCVS, Chief Veterinary & Product Officer of Trupanion, noted, “We’re proud to be at the forefront of the intersection between pet and public health.
  • As discussed by the panel, this could be attributed to respiratory vaccine compliance, increased pet owner awareness and sensitivity to respiratory signs, or pure coincidence.
  • Trupanion's Chief Veterinary and Product Officer, Dr. Steve Weinrauch, is available to share canine respiratory illness related insights or to provide context regarding pet health data as it relates to the extensive Trupanion database.

eGenesis and PorMedTec Announce Successful Production of Genetically Engineered Porcine Donors in Japan

Retrieved on: 
Tuesday, February 13, 2024

eGenesis , a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, and PorMedTec, a global leader in porcine embryology, have successfully produced genetically engineered porcine donors in Japan for use in transplantation.

Key Points: 
  • eGenesis , a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, and PorMedTec, a global leader in porcine embryology, have successfully produced genetically engineered porcine donors in Japan for use in transplantation.
  • As part of a collaboration between the two companies, genetically engineered porcine cells developed by eGenesis were provided to PorMedTec for production using the somatic cell nuclear transfer, or cloning, process.
  • eGenesis and PorMedTec plan to jointly advance the development of genetically engineered organs in Japan to address the massive unmet need in the country, with an initial focus on kidney transplant.
  • “Cloning technology will enable the use of an alternative organ supply using genetically engineered porcine donors.

Adtalem Global Education Names Scott Liles as the New Medical and Veterinary President

Retrieved on: 
Tuesday, February 13, 2024

Adtalem Global Education Inc. (NYSE: ATGE), a national leader in post-secondary education and the nation’s largest healthcare educator1, has appointed Scott Liles as president, Adtalem medical and veterinary, effective April 1.

Key Points: 
  • Adtalem Global Education Inc. (NYSE: ATGE), a national leader in post-secondary education and the nation’s largest healthcare educator1, has appointed Scott Liles as president, Adtalem medical and veterinary, effective April 1.
  • In his new role, Liles will have principal responsibility for the academic, operational and financial outcomes of the Medical and Veterinary reporting segment.
  • His strong business acumen and expertise in leading global organizations make him a fantastic addition to the Adtalem leadership team,” said Steve Beard, president and CEO, Adtalem Global Education.
  • “It’s an honor to rejoin the Adtalem family and be part of the solution to fulfilling the needs of the healthcare workforce while impacting local and global communities,” said Scott Liles, president, Adtalem medical and veterinary.

Zoetis Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Tuesday, February 13, 2024

(NYSE: ZTS) today reported its financial results for the fourth quarter and full year 2023 as well as provided full year guidance for 2024.

Key Points: 
  • (NYSE: ZTS) today reported its financial results for the fourth quarter and full year 2023 as well as provided full year guidance for 2024.
  • The company reported revenue of $2.2 billion for the fourth quarter of 2023, which was an increase of 8% compared with the fourth quarter of 2022, on both a reported and operational1 basis.
  • In the fourth quarter of 2023:
    Revenue in the U.S. segment was $1.2 billion, an increase of 9% compared with the fourth quarter of 2022.
  • Zoetis will host a webcast and conference call at 8:30 a.m. (ET) today, during which company executives will review fourth quarter and full year 2023 results, discuss financial guidance and respond to questions from financial analysts.